Armstrong Advisory Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.5K Hold
116
– – ﹤0.01% 633
2026
Q2
$18.2K Hold
116
– – ﹤0.01% 609
2026
Q1
$17.7K Hold
116
– – ﹤0.01% 589
2025
Q4
$16K Hold
116
– – ﹤0.01% 600
2025
Q3
$14.9K Buy
116
+16
+16% +$1.95K ﹤0.01% 607
2025
Q2
$12.1K Hold
100
– – ﹤0.01% 631
2025
Q1
$9.7K Hold
100
– – ﹤0.01% 632
2024
Q4
$9.7K Hold
100
– – ﹤0.01% 632
2024
Q3
$11.5K Hold
100
– – ﹤0.01% 575
2024
Q2
$10.6K Buy
100
+87
+669% +$8.73K ﹤0.01% 575
2024
Q1
$1.31K Hold
13
– – ﹤0.01% 731
2023
Q4
$1.31K Hold
13
– – ﹤0.01% 731
2023
Q3
$1.32K Hold
13
– – ﹤0.01% 794
2023
Q2
$1.31K Hold
13
– – ﹤0.01% 757
2023
Q1
$1.2K Sell
13
-100
-88% -$8.73K ﹤0.01% 733
2022
Q4
$10.3K Buy
+113
New +$9.5K ﹤0.01% 576

Other funds holding NVS

Armstrong Advisory Group's NVS Position: Q3 2026 in Review

Armstrong Advisory Group held its Novartis (NVS) position steady in Q3 2026 at 116 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #633.

Armstrong Advisory Group first reported a position in NVS in Q4 2022 and has held it in 16 quarters since. The position peaked at $18.2K in Q2 2026. 1,555 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Armstrong Advisory Group held 116 shares of Novartis worth $16.5K as of Q3 2026.
  • Armstrong Advisory Group left its Novartis share count unchanged in Q3 2026.
  • Novartis made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #633 holding.
  • Armstrong Advisory Group first reported a position in Novartis in Q4 2022 and has held it in 16 quarters since.
  • Armstrong Advisory Group's Novartis position peaked at $18.2K in Q2 2026.
  • 1,555 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.